A combination of BRAF and MEK inhibitors plus immunotherapy improved progression-free but not overall survival, compared to dual immune checkpoint blockade.

The Australian company is betting the radionuclide could be an option for patients with HER2-expressing solid tumors who can't tolerate other treatments.

The French company is designing a Phase IIb program to validate the biomarker, which could identify the 30 percent of patients likely to respond to the antibody.

At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.

Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...

Investigators aim to establish an optimal dose and explore CER-1236's safety and preliminary anti-tumor activity.

Two studies presented at ASCO's annual meeting used ctDNA testing to determine which patient might benefit from anti-EGFR retreatment.

UniQure said it has aligned with the FDA on components of a statistical analysis plan for a registrational trial of AMT-130.

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

AstraZeneca's camizestrant and Pfizer's vepdegestrant extended progression-free survival in trials in advanced ESR1-mutated breast cancer.

Researchers at ASCO reviewing data from the ATOMIC trial said they will change practice based on the results but questioned ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line ...